Arbutus Biopharma Misses Q4 EPS by 33c

  • Investing.com
Arbutus Biopharma Misses Q4 EPS by 33c

Arbutus Biopharma (NASDAQ: ABUS ) reported Q4 EPS of ($0.46), $0.33 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $39 million versus the consensus estimate of $6.18 million.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100